Status:
COMPLETED
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia
Lead Sponsor:
GlaxoSmithKline
Conditions:
Androgenetic Alopecia
Eligibility:
MALE
20-50 years
Phase:
PHASE3
Brief Summary
The purpose of this six month study is to show that dutasteride is safe and more effective than placebo, and at least as safe and effective as finasteride in treating hair loss in men with androgeneti...
Detailed Description
Androgenetic alopecia is a common, androgen-induced, pattern of progressive loss of scalp hair with an onset at any age after puberty in genetically predisposed people. The influence of androgens on s...
Eligibility Criteria
Inclusion
- Norwood-Hamilton Type III vertex, IV, or V
Exclusion
- History or evidence of hair loss other than androgenetic alopecia
- Scarring of the scalp
- Use of dutasteride in previous 18 months
- Use of finasteride within previous 12 months
- Hair transplantation or hair weaving within 6 months
- Use of Minoxidil within previous 6 months
- Use of drugs with anti-androgenetic/androgenetic properties within previous 6 months
- Use of Drugs that cause hypertrichosis or hypotrichosis within previous 6 months
- Light or laser treatment of scalp within previous 3 months
- Cosmetic products aimed at improving or correcting signs of hair loss within previous 2 weeks
Key Trial Info
Start Date :
October 28 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 28 2012
Estimated Enrollment :
917 Patients enrolled
Trial Details
Trial ID
NCT01231607
Start Date
October 28 2010
End Date
February 28 2012
Last Update
August 10 2018
Active Locations (39)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
CABA, Buenos Aires, Argentina, C1055AAO
2
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1425BEA
3
GSK Investigational Site
La Boca, Buenos Aires, Argentina, C1155AHD
4
GSK Investigational Site
Buenos Aires, Argentina, 1425